Cerenome, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cerenome, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 6,091% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-48.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 71% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-27.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 62% of Healthcare companies in United States.
Cash Cushion Ratio
+59%Cash, after subtracting all debt, equals 59% of its market value (net cash).
Higher than 80% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 75% of Healthcare companies in United States.
Tangible Net Worth Ratio
82%Of every $100 of net worth, $82 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 63% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Cerenome, Inc. made a loss over the last year. Cerenome, Inc. owes $0.61 for every $1 it owns. Cerenome, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCerenome, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.43The share price is 2.43 times Cerenome, Inc.'s book value per share, lower than 52% of Healthcare companies in United States.
Market cap
$13 MThe total market value of all of Cerenome, Inc.'s shares at today's price (share price × number of shares), smaller than 85% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$5 MWhat Cerenome, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.72Net worth divided by the number of shares. The share price of $1.75 is 2.4 times this, which is the P/B above.
Return on equity (ROE)
-614.0%Cerenome, Inc. lost 614.0% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
Owes vs Owns
0.61×Cerenome, Inc. owes $0.61 for every $1 it owns (moderate), higher than 65% of Healthcare companies in United States.
Dividend yield
NoneCerenome, Inc. does not currently pay a dividend.
Profit growth
LossCerenome, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCerenome, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCerenome, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cerenome, Inc.: $13 M ÷ $5 M (30 Jun 2026) = 2.4.
What is Cerenome, Inc.'s return on equity?
Cerenome, Inc. lost 614.0% of its shareholders' money over the last year, lower than 95% of Healthcare companies in United States.
How much does Cerenome, Inc. owe compared with what it owns?
Cerenome, Inc. owes $0.61 for every $1 it owns (moderate), higher than 65% of Healthcare companies in United States.
Does Cerenome, Inc. pay a dividend?
No. Cerenome, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.